Biogen Inc. (BIIB)

Last Price:  

Company Description

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimer's disease, lupus nephritis to neuropathic pain.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $13.44B
Net Income (Most Recent Fiscal Year) $4.00B
PE Ratio (Current Year Earnings Estimate) 16.08
PE Ratio (Trailing 12 Months) 12.28
PEG Ratio (Long Term Growth Estimate) 1.54
Price to Sales Ratio (Trailing 12 Months) 3.82
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 3.99
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) 7.84
Pre-Tax Margin (Trailing 12 Months) 20.17%
Net Margin (Trailing 12 Months) 16.40%
Return on Equity (Trailing 12 Months) 34.74%
Return on Assets (Trailing 12 Months) 15.37%
Current Ratio (Most Recent Fiscal Quarter) 2.15
Quick Ratio (Most Recent Fiscal Quarter) 1.77
Debt to Common Equity (Most Recent Fiscal Quarter) 0.65
Inventory Turnover (Trailing 12 Months) 1.66
Book Value per Share (Most Recent Fiscal Quarter) $69.44
Earnings per Share (Most Recent Fiscal Quarter) $5.68
Earnings per Share (Most Recent Fiscal Year) $33.70
Diluted Earnings per Share (Trailing 12 Months) $12.46
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers - General
Common Shares Outstanding 149.03M
Free Float 148.11M
Market Capitalization $44.74B
Average Volume (Last 20 Days) 1.00M
Beta (Past 60 Months) 0.41
Percentage Held By Insiders (Latest Annual Proxy Report) 0.62%
Percentage Held By Institutions (Latest 13F Reports) 83.18%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%